Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing
Granite Bio Debuts with $100 Million of Capital
Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.
Product Name : GRT-001
Product Type : Antibody
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing
Reset All
